Intensity Therapeutics Q3 net loss $3.5M; first patient dosed in Phase 2 TNBC study

INTENSITY THERAPEUTICS, INC.

Net loss of $3.5M for Q3 2024 vs $2.3M a year ago; R&D expenses rose to $2.2M.
Cash and equivalents $2.8M as of Sept 30, 2024; expected to fund operations into Q1 2025.
First patient dosed in Phase 2 INVINCIBLE-4 study of INT230-6 in presurgical triple-negative breast cancer.
Phase 3 INVINCIBLE-3 sarcoma study received regulatory authorizations in 8 countries; enrollment target 333 patients.
Regulatory approvals obtained from Health Canada, EMA, Swissmedic, and Australia's TGA during Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.